Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL344744 | 0.97 | TET2 (0.48) | TET2RECQLTSHRHSD17B10GAA | |
| SCHEMBL16532927 | 0.80 | TET2 (0.46) | TET2RECQLTSHRHSD17B10GAA | |
| SCHEMBL21129653 | 0.80 | TET2 (0.46) | TET2RECQLTSHRHSD17B10GAA | |
| SCHEMBL756932 | 0.80 | CA2 (0.39) | GAACA12CA2CA14DPP4 | |
| SCHEMBL6558483 | 0.80 | DPP4 (0.34) | TET2RECQLTSHRGAAMGAM | |
| SCHEMBL15621164 | 0.78 | TET2 (0.45) | TET2RECQLTSHRHSD17B10GAA | |
| SCHEMBL1091517 | 0.78 | GAA (0.54) | TSHRHSD17B10GAAMGAMSI | |
| SCHEMBL17125010 | 0.78 | TET2 (0.45) | TET2RECQLTSHRHSD17B10GAA | |
| SCHEMBL17125032 | 0.78 | TET2 (0.45) | TET2RECQLTSHRHSD17B10GAA | |
| SCHEMBL3267023 | 0.77 | TET2 (0.43) | TET2RECQLTSHRHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-11091511-B2 | Panaxdiol-type ginsenoside derivative, preparation method therefor and use thereof | ARMY MEDICAL UNIVERSITY (CN) | 2021-08-17 | — | — | US | disclosed |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20190307776-A1 | AZA-SUBSTITUTED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2019-10-10 | — | — | US | disclosed |
| US-20190256549-A1 | PANAXDIOL-TYPE GINSENOSIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ARMY MEDICAL UNIVERSITY (CN) | 2019-08-22 | — | — | US | disclosed |
| US-10208035-B2 | Compounds for inhibiting drug-resistant strains of HIV-1 integrase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-02-19 | — | — | US | disclosed |
| WO-2018067704-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| EP-2900642-B1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-20170305904-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2003064456-A1 | TRIPEPTIDES HAVING A HYDROXYPROLINE ETHER OF A SUBSTITUTED QUINOLINE FOR THE INHIBITION OF NS3 (HEPATITIS C) | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-08-07 | — | — | WO | disclosed |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-1286967-A1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-05 | — | — | EP | disclosed |
| EP-1250340-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001087838-A1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001046199-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-0920414-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 1999-06-09 | — | — | EP | disclosed |
| WO-1997049674-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-12-31 | — | — | WO | disclosed |
| US-5438035-A | Herbicides | AMERICAN CYANAMID COMPANY (US) | 1995-08-01 | — | — | US | disclosed |
| EP-0640594-A1 | Hydantoin derivative as metalloprotease inhibitor | FUJIREBIO INC. (JP) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | TET2 4445/4885RECQL 2556/4885TSHR 4576/4885 |
| US-20190256549-A1 | PANAXDIOL-TYPE GINSENOSIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | LDLR, NR1H2, TNF | TET2 1314/4885RECQL 3092/4885TSHR 4585/4885 |
| US-20190307776-A1 | AZA-SUBSTITUTED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | CYP51A1, TYMP, TYMS | TET2 229/4885RECQL 1223/4885TSHR 4673/4885 |
| US-10208035-B2 | Compounds for inhibiting drug-resistant strains of HIV-1 integrase | CCR8, CDK8, CHD8 | TET2 1677/4885RECQL 2546/4885TSHR 310/4885 |
| US-20170305904-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | CCR8, CDK8, CHD8 | TET2 1677/4885RECQL 2546/4885TSHR 310/4885 |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ABCC1, ABCB11, ABCB1 | TET2 4777/4885RECQL 1156/4885TSHR 4206/4885 |
| US-11091511-B2 | Panaxdiol-type ginsenoside derivative, preparation method therefor and use thereof | TNF, NR1H2, LDLR | TET2 1454/4885RECQL 2925/4885TSHR 4552/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | TET2 4369/4885RECQL 1871/4885TSHR 3550/4885 |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | TET2 4369/4885RECQL 1871/4885TSHR 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.